WCN26-4555 Metabolic-Associated Chronic Kidney Disease: A Pilot Study of 32 Patients for Validating the Diagnostic Criteria

Conclusion:This first report of PRO data from C-MAJOR helps inform our understanding of ADPKD impact in patients treated with tolvaptan in Canada.Findings showed people with ADPKD at early-stage CKD had minimally impacted ADPKD-related burden of illness at baseline, with PRO scores remaining constant over time with treatment despite disease progression.Greater improvements in PROs were seen for patients with early-vs late-stage CKD.Rates of PRO completion declined over an extended timeframe, highlighting challenges of gathering such data in real-world settings.I have potential conflict of interest to disclose.Funding for C-MAJOR was provided by Otsuka Canada, as required by Health Canada's mandate that a patient registry be created in order to bring tolvaptan to Canada.I did not use generative AI and AI-assisted technologies in the writing process.